Leonteq Securities AG acquired a new position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) in the fourth quarter, Holdings Channel reports. The fund acquired 27,960 shares of the biotechnology company’s stock, valued at approximately $4,921,000.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. WPG Advisers LLC lifted its holdings in Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 117 shares during the last quarter. Accredited Wealth Management LLC raised its stake in shares of Biogen by 1,233.3% in the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 185 shares during the last quarter. First Horizon Corp bought a new position in shares of Biogen in the fourth quarter worth about $30,000. WFA of San Diego LLC acquired a new stake in shares of Biogen during the 2nd quarter worth approximately $32,000. Finally, GoalVest Advisory LLC bought a new stake in shares of Biogen during the fourth quarter worth approximately $35,000. 87.93% of the stock is owned by institutional investors.
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on the stock. Stifel Nicolaus boosted their price target on shares of Biogen from $202.00 to $214.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. BMO Capital Markets boosted their price target on shares of Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a research note on Friday, February 6th. Argus raised shares of Biogen to a “hold” rating in a research note on Thursday, April 9th. Canaccord Genuity Group boosted their price target on shares of Biogen from $230.00 to $245.00 and gave the stock a “buy” rating in a research note on Wednesday, April 1st. Finally, Morgan Stanley boosted their price target on shares of Biogen from $200.00 to $206.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $215.62.
Biogen Stock Down 1.4%
Shares of NASDAQ BIIB opened at $187.80 on Thursday. Biogen Inc. has a 52-week low of $121.05 and a 52-week high of $205.97. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. The stock has a market cap of $27.73 billion, a P/E ratio of 20.15, a P/E/G ratio of 1.68 and a beta of 0.19. The firm has a 50 day moving average price of $185.39 and a 200 day moving average price of $180.41.
Biogen (NASDAQ:BIIB – Get Free Report) last posted its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping the consensus estimate of $2.95 by $0.62. The company had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period last year, the business posted $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Analysts expect that Biogen Inc. will post 14.18 EPS for the current year.
Biogen Company Profile
Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.
The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.
Featured Articles
- Five stocks we like better than Biogen
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.
